MARKET

MYGN

MYGN

Myriad Genetics
NASDAQ
18.61
-0.62
-3.22%
After Hours: 18.61 0 0.00% 16:20 12/04 EST
OPEN
18.78
PREV CLOSE
19.23
HIGH
19.03
LOW
18.32
VOLUME
696.77K
TURNOVER
0
52 WEEK HIGH
24.21
52 WEEK LOW
13.82
MARKET CAP
1.65B
P/E (TTM)
-5.5333
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at MYGN last week (1127-1201)?
Weekly Report · 1d ago
Weekly Report: what happened at MYGN last week (1120-1124)?
Weekly Report · 11/27 09:11
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
NASDAQ · 11/21 15:54
Myriad Genetics Celebrates One Million SneakPeek Results Shared With Expectant Parents
Myriad genetics has delivered results to one million consumers with sneakpeek early gender dna test. The test is 99% accurate and is one of the earliest ways to learn the sex of a baby's predicted fetal sex. Customers can take the test at home or have blood collected at a local clinic.
Benzinga · 11/20 21:19
Myriad Genetics (MYGN) Expands Pharma Services With New Pact
NASDAQ · 11/20 16:18
Weekly Report: what happened at MYGN last week (1113-1117)?
Weekly Report · 11/20 09:11
Myriad Genetics: Current report
Press release · 11/14 11:05
Myriad Genetics: Prospectus [Rule 424(b)(5)]
Press release · 11/13 12:09
More
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company provides testing that helps assess an individual’s risk for developing disease or disease progression and guides treatment decisions across medical specialties where genetic insights can significantly improve patient health care and lower health care costs, and includes corporate services, such as finance, human resources, legal and information technology. It has three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. Its products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, and EndoPredict, Foresight, Prequel, and SneakPeek and GeneSight.

Webull offers Myriad Genetics, Inc. stock information, including NASDAQ: MYGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MYGN stock methods without spending real money on the virtual paper trading platform.